Welcome to our latest update on the outsourced Pharma Commercialisation Services sector. In this report we will be reviewing deal activity across 2022 and taking a look forward to see what 2023 may hold for the sector.
In our last report, written after the first half of the year, we predicted 2022 would be another record year for commercialisation M&A activity. We were correct! But, given the strength of H1, this was a not a hard prediction to make. Although the market cooled through Autumn, 2022 came out on par with 2021.
With 10 months left, forecasting 2023 is significantly harder – but we are optimistic and, for a number of reasons, see it as being another strong year for commercialisation deal flow.
We hope that you enjoy this report and look forward to discussing the data and underlying themes with you.